Boston Scientific BSX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 274.5%-1.3pp | 275.8%-1.6pp | 277.4%+1.9pp | 275.5%+7.5pp | |
| Operating margin | 69.1%+4.8pp | 64.3%+5.2pp | 59.1%+12.3pp | 46.8%— | |
| Net margin | 53.8%+7.6pp | 46.3%+12.4pp | 33.8%+9.3pp | 24.5%— | |
| Returns | |||||
| Return on equity | 46.5%+9.6pp | 36.8%+11.1pp | 25.7%+7.5pp | 18.2%— | |
| Return on invested capital | 35.2%+7.1pp | 28.2%+7.9pp | 20.3%+3.2pp | 17.1%— | |
| Efficiency | |||||
| Asset turnover | 1.9×+0.1× | 1.7×+0.1× | 1.6×+0.1× | 1.6×+0.1× | |
| Liquidity | |||||
| Current ratio | 5.9×+0.1× | 5.8×+0.4× | 5.4×0.0× | 5.5×-1.0× | |
| Leverage | |||||
| Debt-to-equity | 1.6×-0.5× | 2.1×+0.1× | 2×-0.1× | 2.2×-0.2× | |
| Net debt / EBITDA | 7.6×-3.6× | 11.2×-0.3× | 11.5×-2.6× | 14.1×— | |
| Per Share | |||||
| Book value per share | $61.74+10.8% | $55.75+9.7% | $50.84+5.7% | $48.09+6.4% | |
| Valuation | |||||
| Market capitalization | $589.26B+25.7% | $468.94B+50.5% | $311.68B+30.8% | $238.31B0.0% | |
| Price / earnings | 236.2×-23.1× | 259.4×-21.8× | 281.1×-37.1× | 318.3×— | |
| Price / sales | 31.3×+1.4× | 29.9×+7.0× | 22.9×+3.7× | 19.2×-2.2× | |
| Price / book | 25.6×+3.0× | 22.6×+5.8× | 16.8×+3.0× | 13.8×-0.9× | |
| EV / EBITDA | 136.6×+0.5× | 136.1×+26.5× | 109.6×+2.9× | 106.7×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Boston Scientific's profit margins?
- Boston Scientific (BSX) runs a 69.2% gross margin and a 18.4% operating margin, with a 17.3% net margin.
- Where do Boston Scientific's ratios come from?
- Every ratio is computed from Boston Scientific's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
